Should You Buy Lexaria Biosciences Stock?

Lexaria Bioscience Corp (LXRP) is a Canadian research-driven company and an innovator in the oral drug delivery platform. It primarily focuses on the development and licensing of DehydraTECH to other companies for the rapid delivery of bioactive compounds in oral and topical products and enhanced customer experience. From gaining the first patent application in 2014 to having 17 granted patents and about 60 patent applications pending around the world, Lexaria has come a long way – but should you buy Lexaria Biosciences stock?

[stock_market_widget type=”combo” symbol=”LXRP” template=”tablechart” color=”default” fields=”virtual.symbol,virtual.name,quote.regularMarketPrice,quote.regularMarketChange,quote.regularMarketChangePercent” chart=”line” range=”1y” interval=”1d” line-color=”rgb(0, 128, 0)”]

A Boom in B2B CBD Powder Processing Sales

The global CBD market was a $2.19 Billion market in 2019 and is expected to reach $39.99 Billion by 2027. Lexaria started its business aiming to enhance the CBD delivery system and has been quite successful in doing so. CBD is also being recognized around the world for its significant medical properties.

Lexaria’s DehydraTECH patent was granted in Europe and Australia for treating central nervous system disorders using CBD and now Lexaria is looking forward to seeking international expansion for the same.

Currently, it serves huge volumes of its patented DehydraTECH enabled CBD powders to business houses and the volume of sales achieved is astonishing considering the company’s expectations. During the past quarter, confirmed purchase orders to process about 8 million servings were being received and orders are expected to rise in 2021. Previously to this quarter Lexaria had reported a whopping 500% volume gain in Q4 of the fiscal year 2020 ending 31^st August 2020.

Considering the robust demand, Lexaria’s hemp business division has decided to discontinue direct B2C product sales and focus on the high-growth oriented B2B CBD powder processing segment while also continuing with the licensing of its intellectual properties to third parties who intend to improve their customer experiences using Lexaria’s technology in the hemp-derived CBD offerings.

CBD for Cardiovascular Diseases

Out of the $47.29 billion global drug market for heart diseases, 90% is comprised of anticoagulants, antihypertensive, and antihyperlipidemic drugs, and obesity and old age has been fueling the market’s growth to make it a $63.96 billion market by 2026.

In 2016 about 840,678 people in the US died because of heart diseases and it is said about 1/3^rd of the population suffers from cardiovascular diseases providing a big market opportunity for companies.

Only about 6% of orally injected drugs find their way into blood circulation. Lexaria’s DehydraTECH processed CBD has vasodilatory potential and can promote better absorption in the blood circulation by 100% – 500%. It also has plans to commence a second exploratory human clinical study to corroborate its initial findings.

If the study is successful, Lexaria might become a top name in the cardiovascular drug industry by introducing its DehydraTECH’s enhanced technology.

Antiviral drugs that can Potentially Help in Curbing COVID-19

Viral diseases are one of the chief causes of death around the world therefore are a big market for pharma companies. Recently, the coronavirus alone had affected around 50 million people around the globe.

Lexaria believes that its advanced DehydraTECH technology is capable of improving the delivery performance of the existing antiviral drugs by dosing them via oral tablets or capsules which would be less expensive and would help in treating more patients in a shorter period.

DehydraTECH has been clinically studied with CBD and Nicotine to date for being active pharmaceutical ingredients. Now Lexaria has been studying its effectiveness in targeting the main protease associated with SARS-CoV-2 infection. If things materialize, it can be a turning point for the company.

Lexaria Bioscience has improved a lot and also has huge growth potential. Its plans look exciting and, if everything goes right, then the stock price can zoom. The stock is currently trading at [stock_market_widget type=”inline” symbol=”LXRP” template=”basic” color=”default”] and while analysts have given it a target of $1.2. It wouldn’t be prudent to allocate a large part of your investment into this stock. Lexaria can be considered for a small percentage of your portfolio and you have the chance to benefit from exponential gains.

Lexaria Bioscience Corp is a Canadian research-driven company and an innovator in the oral drug delivery platform. It primarily focuses on the development and licensing of DehydraTECH to other companies for the rapid delivery of bioactive compounds in oral and topical products and enhanced customer experience.

From gaining the first patent application in 2014 to having 17 granted parents and about 60 patent applications pending around the world, Lexaria has come a long way.

A Boom in B2B CBD Powder Processing Sales

CBD for Cardiovascular Diseases

In 2016, about 840,678 people in the US died because of heart disease and it is said about 1/3^rd of the population suffers from cardiovascular diseases providing a big market opportunity for companies.

If the study is successful, Lexaria might become a top name in the cardiovascular drug industry by introducing its DehydraTECH’s enhanced technology.

Antiviral drugs that can Potentially Curb COVID-19

Lexaria Bioscience has improved a lot and also has huge growth potential. Its plans look exciting and if everything goes right then the stock price can zoom. The stock is currently trading at $0.24 and while analysts have given it a target of $1.2. It wouldn’t be prudent to allocate a large part of your investment into this stock. Lexaria can be considered for a small percentage of your portfolio – with such a promising chance to benefit from exponential gains.

Should You Buy Lexaria Biosciences Stock?

Cannin Investment Group: Your Hemp Stocks Experts

Cannin.com is your trusted resource for hemp stocks. Our team of financial experts evaluates all emerging hemp stock investing opportunities. We aggregate hundreds of hours of market research to provide tips on the best hemp stocks for 2020.

Use Cannin as your resource for:

Is it too late to invest in hemp stocks? No! This is the perfect time to invest.

Wall Street analysts expect the global cannabis industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in hemp stocks is now.

Are you interested in hemp stocks like GW Pharmaceuticals, Charlotte’s Web, Canopy Growth, or Hemp Inc.?

Are you looking to buy stock in hemp companies or marijuana companies in 2020? Interested in emerging penny hemp stocks? Interested in leveraging the power of algorithmic stock trades to profit from hemp stocks? Looking for the best Canadian cannabis stocks to invest in? We can help.

Predict price movements of hemp stocks several hours in advance with our proprietary algorithmic stock trading software.

+25% Gains in 2020
+49.8% Gains in 2019
Backtested since 2012

At Cannin, we’re so confident you’ll love our algotrading hemp stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best hemp stocks – we’ll show you how at cannin.com.

Should You Buy Lexaria Biosciences Stock?